Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

ABSTRACT:

Importance

Among patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown.

Objective

To investigate the effect of tesamorelin on visceral and liver fat.

Design, setting, and patients

Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation at Massachusetts General Hospital in Boston. The first patient was enrolled on January 10, 2011; for the final patient, the 6-month study visit was completed on September 6, 2013.

Interventions

Partici

SUBMITTER: Stanley TL 

PROVIDER: S-EPMC4363137 | biostudies-literature | 2014 Jul 23-30

REPOSITORIES: biostudies-literature